| Literature DB >> 34025074 |
Maria Conticchio1, Riccardo Inchingolo2, Antonella Delvecchio3, Letizia Laera4, Francesca Ratti5, Maximiliano Gelli6, Ferdinando Anelli7, Alexis Laurent8, Giulio Vitali9, Paolo Magistri10, Giacomo Assirati10, Emanuele Felli11, Taiga Wakabayashi12, Patrick Pessaux13, Tullio Piardi14, Fabrizio di Benedetto10, Nicola de'Angelis15, Javier Briceño16, Antonio Rampoldi17, Renè Adam18, Daniel Cherqui19, Luca Antonio Aldrighetti20, Riccardo Memeo21.
Abstract
BACKGROUND: Surgical resection and radiofrequency ablation (RFA) represent two possible strategy in treatment of hepatocellular carcinoma (HCC) in Milan criteria. AIM: To evaluate short- and long-term outcome in elderly patients (> 70 years) with HCC in Milan criteria, which underwent liver resection (LR) or RFA.Entities:
Keywords: Elderly patients; Hepatocellular carcinoma; Milan criteria; Propensity score matching; Radiofrequency ablation; Surgical resection
Year: 2021 PMID: 34025074 PMCID: PMC8117730 DOI: 10.3748/wjg.v27.i18.2205
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742
Preoperative and clinical characteristics of patients with hepatocellular carcinoma in Milan criteria who underwent surgical resection and radiofrequency ablation
|
|
| |||||
|
|
|
|
|
|
| |
| Male, | 116 (70) | 319 (74) | 0.35 | 98 (72) | 104 (76) | 0.48 |
| Age (yr) median (range) | 75 (70-89) | 74.9 (70-90) | 0.71 | 75 (70-88) | 74.7 (70-86.1) | 0.56 |
| BMI (kg/cm²) median (range) | 26.7 (19-51) | 26.7 (19-52) | 0.37 | 26.7 (19-51) | 26 (21-41) | 0.85 |
| Co-morbidities > 2, | 107 (64) | 142 (33) | 0.001 | 83 (61) | 81 (60) | 0.90 |
| Cause of Cirrhosis | 0.002 | 0.11 | ||||
| Hepatitis C virus | 89 (54) | 217 (50) | 73 (54) | 68 (50) | ||
| Hepatitis B virus | 10 (6) | 80 (19) | 10 (7) | 22 (16) | ||
| Alcohol | 37 (22) | 60 (14) | 31(23) | 23 (17) | ||
| Others | 29 (18) | 72 (17) | 22 (16) | 23 (17) | ||
| ASA score, | 0.004 | 0.59 | ||||
| I-II | 45 (27) | 172 (40) | 41 (30) | 36 (26) | ||
| III-IV | 120 (73) | 257 (60) | 95 (70) | 100 (74) | ||
| Blood tests median (range) | ||||||
| Bilirubin (mg/dL) | 1 (0.2-2.8) | 0.9 (0.18-4.5) | 0.41 | 1 (0.2-2.8) | 0.8 (0.2-4.5) | 0.02 |
| Creatinine (mg/dL) | 0.9 (0.5-2.5) | 1 (0.2-2.5) | 0.03 | 0.9 (0.5-2.3) | 0.9 (0.4-2.5) | 0.02 |
| Platelet count × 109/L | 131 (10-856) | 178 (45-900) | 0.00 | 131.5 (10-856) | 155 (47-573) | 0.57 |
| INR | 1.1 (0.9-2.4) | 1.2 (0.6-2.5) | 0.00 | 1.1 (0.9-2.4) | 1.1 (0.8-2.5) | 0.00 |
| Child Pugh, | 0.52 | 0.87 | ||||
| A | 139 (84) | 370 (86) | 114 (84) | 116 (85) | ||
| B | 26 (16) | 59 (14) | 22 (16) | 20 (15) | ||
| MELD median (range) | 8 (6-18) | 6 (6-17) | 0.00 | 8 (6-18) | 8 (6-17) | 0.05 |
| Tumors number, | 0.07 | 0.71 | ||||
| Single nodule | 142 (86) | 392 (91) | 117 (86) | 120 (88) | ||
| Multi nodules | 23 (14) | 37 (9) | 19 (14) | 16 (12) | ||
| Tumor size (mm) | 24 (10-50) | 30 (7-50) | 0.00 | 25 (10-50) | 24.5 (7-50) | 0.9 |
| < 20 | 49 (30) | 33 (8) | 0.00 | 36 (26) | 28 (21) | 0.31 |
| 20-50 | 116 (70) | 396 (92) | 100 (74) | 108 (79) | ||
| Bilobar tumor, | 8 (5) | 8 (2) | 0.08 | 6 (4) | 2 (1) | 0.28 |
| Tumor location, | 0.28 | 0.17 | ||||
| 1 | 2 (1) | 8 (2) | 1 (0.7) | 1 (0.7) | ||
| 2 | 14 (8) | 41 (10) | 13 (9) | 14 (10) | ||
| 3 | 12 (7) | 42 (10) | 10 (7) | 20 (15) | ||
| 4 | 20 (12) | 53 (12) | 15 (11) | 13 (9) | ||
| 5 | 28 (17) | 63 (15) | 21 (15) | 27 (19) | ||
| 6 | 27 (16) | 87 (20) | 23 (17) | 29 (21) | ||
| 7 | 18 (11) | 60 (14) | 16 (12) | 11 (8) | ||
| 8 | 44 (28) | 75 (17) | 37 (27) | 21 (15) | ||
| Histologically proven, | 42 (25) | 115 (27) | 0.75 | 36 (26) | 42 (31) | 0.50 |
| Previous treatment, | 53 (32) | 53 (12) | 0.00 | 42 (31) | 21 (15) | 0.004 |
Continuous variables were compared using an independent sample t-test and Mann-Whitney U test. Categorical variables were compared using the chi-square test and Kruskal-Wallis test respectively. PSM: Propensity score matching; BMI: Body mass index; ASA: American Society of Anesthesiologists; MELD: Model for End-Stage Liver Disease; RFA: Radiofrequency ablation; INR: International normalized ratio.
Clinical and perioperative characteristics of patients with hepatocellular carcinoma in Milan criteria who underwent surgical resection and radiofrequency ablation
|
|
| |||||
|
|
|
|
|
|
| |
| Operative time (min) median (range) | 25 (5-250) | 205 (55-600) | 0.002 | 25 (5-250) | 190 (55-600) | 0.001 |
| Blood transfusion, | 13 (8) | 66 (15) | 0.01 | 11(8) | 23 (17) | 0.04 |
| Dindo-Clavien Classification, | 0.001 | 0.002 | ||||
| I-II | 163 (99) | 378 (91) | 134 (98) | 121 (89) | ||
| III-IV | 2 (1) | 38 (9) | 2 (1) | 15 (11) | ||
| Postoperative complication, | 0.001 | 0.002 | ||||
| Yes | 31 (19) | 188 (44) | 28 (21) | 75 (55) | ||
| No | 134 (81) | 241 (56) | 108 (79) | 61 (45) | ||
| Type of complication, | ||||||
| Liver failure | 1 (1) | 35 (8) | 0.002 | 1 (0.7) | 14 (10) | 0.001 |
| Ascites | 3 (2) | 60 (14) | 0.003 | 3 (2) | 17 (12) | 0.002 |
| Biliary leakage | 0 (0) | 9 (2) | 0.064 | 0 (0) | 3 (2) | 0.25 |
| Hemorrhage | 4 (2) | 19 (4) | 0.340 | 3 (2) | 11 (8) | 0.51 |
| Systemic Infection | 4 (2) | 30 (7) | 0.03 | 4 (3) | 14 (10) | 0.03 |
| Intra-abdominal abscess | 0 (0) | 23 (5) | 0.00 | 0 (0) | 8 (6) | 0.007 |
| Wound infection | 2 (1) | 12 (3) | 0.37 | 2 (1) | 7 (5) | 0.17 |
| Portal thrombosis | 1 (1) | 3 (1) | 1.007 | 1 (0.7) | 2 (1) | 1 |
| Pulmonary | 7 (4) | 33 (8) | 0.15 | 6 (4) | 15 (11) | 0.07 |
| Cardiac | 1 (1) | 18 (4) | 0.03 | 1 (0.7) | 8 (6) | 0.03 |
| Renal | 1 (1) | 18 (4) | 0.03 | 1 (0.7) | 6 (4) | 0.12 |
| Reoperation, | 0 (0) | 7 (2) | 0.19 | 0 (0) | 2 (1) | 0.5 |
| Postoperative treatment, | 3 (2) | 19 (4) | 0.15 | 3 (2) | 10 (7) | 0.08 |
| Length of hospital stay median (range) | 2 (1-23) | 6 (1-203) | 0.00 | 2 (1-23) | 7 (1-203) | 0.00 |
| Mortality 90 d, | 3 (2) | 13 (3) | 0.001 | 3 (2) | 4 (3) | 1 |
Continuous variables were compared using an independent sample t-test and Mann-Whitney U test. Categorical variables were compared using the chi-square test and Kruskal-Wallis test respectively. PSM: Propensity score matching; RFA: Radiofrequency ablation.
Figure 1Survival curves (Kaplan-Meier method) of patients with hepatocellular carcinoma in Milan criteria who underwent surgical resection and radiofrequency ablation before propensity score matching. Overall survival curves were constructed using the Kaplan-Meier method and compared using the log-rank test. Overall survival significantly differs between the two groups. PSM: Propensity score matching; OS: Overall survival; RES: Resection; RFA: Radiofrequency ablation.
Figure 2Tumor recurrence curves (Kaplan-Meier method) of patients with hepatocellular carcinoma in Milan criteria who underwent surgical resection and radiofrequency ablation before propensity score matching. Recurrence-free survival curves were constructed using the Kaplan-Meier method and compared using the log-rank test. hepatocellular carcinoma recurrence significantly differs between the two groups. PSM: Propensity score matching; DFS: Disease-free survival; RES: Resection; RFA: Radiofrequency ablation.
Figure 3Survival curves (Kaplan-Meier method) of patients with hepatocellular carcinoma in Milan criteria who underwent surgical resection and radiofrequency ablation after propensity score matching. Overall survival curves were constructed using the Kaplan-Meier method and compared using the log-rank test. After propensity score matching, survival remained significantly different. PSM: Propensity score matching; OS: Overall survival; RES: Resection; RFA: Radiofrequency ablation.
Figure 4Tumor recurrence curves (Kaplan-Meier method) of patients with hepatocellular carcinoma in Milan criteria who underwent surgical resection and radiofrequency ablation after propensity score matching. Recurrence-free survival curves were constructed using the Kaplan-Meier method and compared using the log-rank test. After propensity score matching, recurrence remained significantly different. PSM: Propensity score matching; DFS: Disease-free survival; RES: Resection; RFA: Radiofrequency ablation.
Univariate and multivariate models for survival
|
|
|
| |
|
|
|
| |
| RFA | 0.001 | 1.46 (1.1-1.79) | 0.001 |
| Age ≤ 75 yr | 0.63 | ||
| Male | 0.001 | ||
| Co-morbidity ≥ 2 | 0.001 | ||
| BMI < 24 | 0.001 | ||
| ASA score III-IV | 0.07 | ||
| TBil (mg/dL > 2) | 0.001 | ||
| Crea (mg/dL > 1) | 0.57 | ||
| PLT (U/μL > 150 × 10³) | 0.001 | ||
| INR (> 1.3) | 0.001 | 1.60 (1.03-2.49) | 0.03 |
| Tumor size < 3 cm | 0.001 | ||
| Multiple nodule | 0.001 | 1.19 (1.08-4.17) | 0.03 |
| Child Pugh A | 0.001 | ||
| MELD > 10 | 0.007 | 1.89 (1.21-2.92) | 0.005 |
The relative prognostic significance of the variables in predicting overall survival and overall recurrence was established using univariate and multivariate Cox proportional hazards regression models. Radiofrequency ablation, international normalized ratio > 1.3 mg/dL, and Model for End-Stage Liver Disease score >10 were independent risk factors for overall survival. RFA: Radiofrequency ablation; INR: International normalized ratio; MELD: Model for End-Stage Liver Disease; RR: Relative risk; CI: Confidence interval; BMI: Body mass index; ASA: American Society of Anesthesiologists; PLT: Platelets; TBil: Total bilirubin; Crea: Creatinine.
Univariate and multivariate models for recurrence
|
|
|
| |
|
|
|
| |
| RFA | 0.001 | 1.37 (1.17-1.60) | 0.0001 |
| Age ≤ 75 yr | 0.28 | ||
| Male | 0.91 | ||
| Co-morbidity ≥ 2 | 0.01 | ||
| BMI < 24 | 0.61 | ||
| ASA score III-IV | 0.61 | ||
| Bilirubin (mg/dL > 2) | 0.37 | ||
| Creatinine (mg/dL > 1) | 0.62 | ||
| PLT (U/μL > 150 × 10³) | 0.001 | ||
| INR (> 1.3) | 0.02 | ||
| Tumor size < 3 cm | 0.001 | ||
| Multiple nodule | 0.07 | ||
| Child Pugh A | 0.26 | ||
| MELD > 10 | 0.01 | 1.51 (1.04-2.17) | 0.03 |
The relative prognostic significance of the variables in predicting overall survival and overall recurrence was established using univariate and multivariate Cox proportional hazards regression models. Radiofrequency ablation and Model for End-Stage Liver Disease score > 10 were considered poor prognostic factors. RFA: Radiofrequency ablation; INR: International normalized ratio; MELD: Model for End-Stage Liver Disease; RR: Relative risk; CI: Confidence interval; BMI: Body mass index; ASA: American Society of Anesthesiologists; PLT: Platelets.